Jensen BV - Search Results

1

Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab.

Boisen MK, Dehlendorff C, Linnemann D, Nielsen BS, Larsen JS, Osterlind K, Nielsen SE, Tarpgaard LS, Qvortrup C, Pfeiffer P, Holländer NH, Keldsen N, Hansen TF, Jensen BB, Høgdall EV, Jensen BV, Johansen JS. Boisen MK, et al. Among authors: jensen bv, jensen bb. PLoS One. 2014 Oct 15;9(10):e109430. doi: 10.1371/journal.pone.0109430. eCollection 2014. PLoS One. 2014. PMID: 25329796 Free PMC article.

2

Extracellular matrix building marked by the N-terminal propeptide of procollagen type I reflect aggressiveness of recurrent breast cancer.

Jensen BV, Johansen JS, Skovsgaard T, Brandt J, Teisner B. Jensen BV, et al. Int J Cancer. 2002 Apr 1;98(4):582-9. doi: 10.1002/ijc.10187. Int J Cancer. 2002. PMID: 11920619 Free article.

3

High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer.

Jensen BV, Johansen JS, Price PA. Jensen BV, et al. Clin Cancer Res. 2003 Oct 1;9(12):4423-34. Clin Cancer Res. 2003. PMID: 14555515

4

[Drug therapy of patients with metastatic colorectal cancer].

Pfeiffer P, Jensen BV. Pfeiffer P, et al. Among authors: jensen bv. Ugeskr Laeger. 2005 Nov 7;167(45):4261-5. Ugeskr Laeger. 2005. PMID: 16277924 Review. Danish.

5

Serum YKL-40, a new prognostic biomarker in cancer patients?

Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Johansen JS, et al. Among authors: jensen bv. Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):194-202. doi: 10.1158/1055-9965.EPI-05-0011. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16492905 Review.

6

Re-treatment with cetuximab in patients with severe hypersensitivity reactions to cetuximab. Two case reports.

Nielsen DL, Pfeiffer P, Jensen BV. Nielsen DL, et al. Among authors: jensen bv. Acta Oncol. 2006;45(8):1137-8. doi: 10.1080/02841860600871764. Acta Oncol. 2006. PMID: 17118853 No abstract available.

7

Is YKL-40 a new therapeutic target in cancer?

Johansen JS, Jensen BV, Roslind A, Price PA. Johansen JS, et al. Among authors: jensen bv. Expert Opin Ther Targets. 2007 Feb;11(2):219-34. doi: 10.1517/14728222.11.2.219. Expert Opin Ther Targets. 2007. PMID: 17227236 Review.

8

Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer.

Dupont J, Jensen HA, Jensen BV, Pfeiffer P. Dupont J, et al. Among authors: jensen bv, jensen ha. Acta Oncol. 2007;46(3):330-5. doi: 10.1080/02841860600949578. Acta Oncol. 2007. PMID: 17450468 Clinical Trial.

9

Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil.

Pfeiffer P, Nielsen D, Yilmaz M, Iversen A, Vejlø C, Jensen BV. Pfeiffer P, et al. Among authors: jensen bv. Acta Oncol. 2007;46(5):697-701. doi: 10.1080/02841860601009455. Acta Oncol. 2007. PMID: 17562448

10

Six cases of treatment with panitumumab in patients with severe hypersensitivity reactions to cetuximab.

Nielsen DL, Pfeiffer P, Jensen BV. Nielsen DL, et al. Among authors: jensen bv. Ann Oncol. 2009 Apr;20(4):798. doi: 10.1093/annonc/mdp040. Epub 2009 Mar 2. Ann Oncol. 2009. PMID: 19254943 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

122 results

Search Page